Immunovaccine Inc., a clinical stage immuno-oncology company, today announced that the first patient has been treated in a Phase 2…
Paradigm Biopharmaceuticals (ASX: PAR) is surpassing its own expectations in recruiting patients for its two phase two clinical trials, which…
miRagen Therapeutics, Inc, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today the initiation…
Syneos Health™, the only fully integrated biopharmaceutical solutions organization, today announced that the company is a founding member of Align…
Elligo Health Research receives $16 million to expand its programs. Austin, Texas-based Elligo Health Research is a company focused on…
First allogeneic stem cell therapy to receive central marketing authorization approval in Europe Alofisel offers a new treatment option…
Pharmaceutical company in Japan unifies product quality management processes across global stakeholders Veeva Systems today announced that Shionogi & Co.,…
Potentially first new class of antibiotics in Phase III development against Gramnegative pathogens in 50 years Polyphor today announced the…
